Clinical research organisation Venn Life Sciences Holdings plans to be a consolidator in the European clinical research market. Venn moved from ISDX to Aim following the reversal of the Venn business into Armscote in return for 9.6m shares at 30p each. A placing at 30p a share raised £2.5m (£2.05m net) for the company, while shareholders who swapped their stake in the core business for shares in the quoted company raised £460,000. Venn was valued at £6m at the placing price.
Sector: Health
Keep up to date with articles published at AIMMicro.com. Subscribe to AIM Micro RSS Feeds